Fontana Expands Revenue Base, But Integration and Hurricane Costs Weigh on Profit in FY 2026

• Despite improved topline, Fontana Limited (FTNA) reported a 12.9% decline in net profit to $507.80Mn for the year ended June 30, 2026, from a restated $583.09Mn in FY2025. The weaker earnings reflected one-off disruption costs associated with Hurricane Melissa, alongside higher financing and amortisation expenses related to its acquisition of Monarch Pharmacy in March 2025.
• Buoyed by continued same-store sales growth, increased customer activity, and a growing contribution from the four Monarch Pharmacy locations, revenue was up 12.4% to $10.70Bn.
• However, the stronger top-line performance was accompanied by faster growth in its cost base, with cost of sales increasing 13.2% to $6.68Bn. As a result, gross margin narrowed by 44 basis points to 37.6%. The margin compression reflected lower sales volumes of higher-margin products at the Western locations, which were significantly affected by Hurricane Melissa, as well as a $15.81Bn inventory write-off related to hurricane damage.
• Total operating expenses (Opex) increased 18.3% to $3.36Bn, outpacing revenue growth, with administrative and other expenses rising 19.2% to $3.26Bn. Higher staff and support costs associated with expanded operations, integration and one-time expenses related to the Monarch acquisition, and set-up costs for its new Ora concept stores were the primary drivers of the increase in Opex. The temporary costs from store closures, reduced trading hours, and ramp-up activities at newly acquired and opened locations.
• The bottom line was further compounded by finance costs, which rose 12.5% to $280.89Mn, reflecting higher loan interest, which more than doubled by 105.7% to $128.52Mn. The increase reflected the additional costs associated with the $300Mn Tranche B senior unsecured bond raised during the year to support working capital requirements.
• Looking ahead, Fontana remains focused on completing the integration of Monarch locations, expanding the Ora by Fontana beauty and skincare concept (including a planned Sovereign Centre location), and pursuing further network growth, with management continuing to note improving revenue-to-expense alignment across the acquired stores as integration matures.
• However, there are risks. Escalating geopolitical tensions could disrupt the supply of imported goods, increase input and procurement costs, and ultimately weigh on revenue growth if product availability is constrained or higher costs are passed on to customers. Additionally, rising inflation presents significant risks to consumer spending and demand for Fontana’s products due to weaker purchasing power. Fontana also carries elevated finance costs following its recent bond issuances, and its goodwill balance of $698.3Mn (arising from the Barbican and Monarch acquisitions) remains subject to annual impairment testing, a matter auditors flagged as a key audit matter. That said, no impairment was identified as at FY 2026 year-end.
• At the close of trading on September 14, 2026, FTNA's share price was J$6.18, representing a 20.7% decline year-to-date. At this level, the stock trades at a P/E of 16.7x, which is in line with the Junior Market Distribution Sector average of 16.6x.

(Sources: JSE & NCBCM Research)